Chronic Care Management/COVID-19 Data Assessment Helps Payers Improve Outcomes for Members with Chronic Disease

Verinovum is now offering free data assessments to help payers analyze the quality and completeness of their patient clinical data necessary to identify and provide care for specific chronic disease states that render their members vulnerable to COVID-19.

Verinovum’s COVID-19 related chronic condition data assessment helps payers assess the quality of their clinical data for these specific conditions and pinpoint exactly which data elements are needed for each member cohort. The assessment involves two phases: within 60 days of receiving raw clinical data, Verinovum delivers a high-level report identifying gaps in overall data completeness. Then, 30 days thereafter, Verinovum highlights areas where significant data enrichment improvements are possible for specific chronic disease use cases such as asthma or diabetes, including medications, diagnosis, procedures, lab results, vital signs, and more.

Due to the urgency and gravity of the pandemic, the assessment is being made available to payers at no cost as part of Verinovum’s ongoing commitment to helping healthcare organizations combat COVID-19.

As an example of how Verinovum helps improve data quality, in a recent engagement with a major national health plan, only 14% of the raw clinical data had the proper structure and requisite data elements to support advanced clinical and analytical use cases. After Verinovum curated and enriched the data, more than 89% was usable, directly impacting patient outcomes and dramatically improving data integrity for use with downstream applications.

“In the aftermath of the initial COVID-19 pandemic, payers are now asking how they can more accurately identify their most at-risk populations. And many have found it’s only by integrating, cleansing and enriching clinical data that they can finally connect the dots and serve their most vulnerable chronically ill members,” says Verinovum CEO Mark McCurry. “As we continue to face the COVID-19 crisis to varying degrees, payers need to proactively intervene with those who have co-related chronic diseases, including those with asthma, CHF, COPD, and diabetes to manage future medical costs and ensure their long-term health and well-being.”